Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Chemokine Receptors in Cancer summarizes the growing body of evidence that several chemokine receptors contribute to tumor behavior. Chemokine receptors were first identified on leukocytes and mediate directed migration of many host cells to sites of ligand expression. It is now well established that most malignant cells also express one or more chemokine receptor. This book describes our current understanding regarding how chemokine receptors contribute to tumor cell migration as well as cell survival and proliferation. The function of chemokine receptors expressed on host cells including antitumor immune effector cells as well as angiostatic and angiogeneic functions of chemokines acting on endothelial cells are described. The role of chemokine receptors that act as decoy receptors is also summarized. The therapeutic potential and challenges of targeting chemokine receptors or cognate ligands is also addressed.

Cancer cells --- Chemokines --- Receptors, Cytokine --- Antigens, CD --- Receptors, G-Protein-Coupled --- Diseases --- Angiogenesis Modulating Agents --- Growth Substances --- Receptors, Immunologic --- Antigens, Differentiation --- Receptors, Cell Surface --- Membrane Proteins --- Biological Markers --- Antigens, Surface --- Physiological Effects of Drugs --- Pharmacologic Actions --- Proteins --- Antigens --- Biological Factors --- Amino Acids, Peptides, and Proteins --- Chemicals and Drugs --- Chemical Actions and Uses --- Angiogenesis Inducing Agents --- Neoplasms --- Receptors, Chemokine --- Biology --- Health & Biological Sciences --- Medicine --- Pharmacy, Therapeutics, & Pharmacology --- Oncology --- Microbiology & Immunology --- Growth --- Regulation. --- Receptors --- Effect of drugs on. --- Effect of drugs on --- Regulation --- Chemokines. --- Drug receptors. --- Drugs --- Receptors, Drug --- Chemotactic cytokines --- Inflammatory peptides --- Intercrines --- Medicine. --- Cancer research. --- Oncology. --- Biomedicine. --- Cancer Research. --- Cell receptors --- Cytokines --- Inflammation --- Peptides --- Mediators --- Oncology  . --- Tumors --- Cancer research

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Tumour survival and growth is critically dependent on an independent blood supply. As such tumour vasculature presents an ideal target for cancer therapy that is widely applicable, accessible and genetically stable rendering it less prone to resistance. Two approaches have been explored for cancer therapy; firstly the prevention of new vessel formation with inhibitors of angiogenesis, and secondly the destruction of existing tumour blood vessels with so called vascular disruptive agents (VDAs). While the first approach appears to delay tumour progression, the second has the potential to cause massive cell death and tumour regression. It is the second approach of vascular targeting that is the focus of this book. Since the tubulin binding agent combretastatin, derived from the bark of the African bush willow, was discovered by George R Pettit to have antimitotic properties over twenty years ago, the field of vascular targeting has expanded steadily. Coincident with the preclinical and clinical development of these agents, there have been advances in our understanding of their mechanism of action and in the technology required to assess their effects. This book aims to provide a comprehensive account of the current state of the art. Preclinical target identification and validation are discussed and the optimum pre-clinical animal models described. The imaging modalities that can be used to assess the efficacy of these agents are examined and a comprehensive review of the clinical development of key drugs is provided. Finally, the recent research exploring rational combinations of VDAs with other agents is reviewed and the potential place of VDAs in the future of cancer therapy is critically appraised.

Cancer -- Chemotherapy. --- Drug targeting. --- Tumors -- Blood-vessels. --- Tumors --- Cancer --- Drug targeting --- Antineoplastic Agents --- Angiogenesis Modulating Agents --- Diseases --- Growth Inhibitors --- Therapeutics --- Growth Substances --- Therapeutic Uses --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Angiogenesis Inhibitors --- Drug Therapy --- Drug Delivery Systems --- Neoplasms --- Physiological Effects of Drugs --- Pharmacologic Actions --- Chemical Actions and Uses --- Chemicals and Drugs --- Medicine --- Health & Biological Sciences --- Oncology --- Blood-vessels --- Chemotherapy --- Oncology. --- Treatment. --- Cancer therapy --- Cancer treatment --- Therapy --- Medicine. --- Cancer research. --- Pharmacology. --- Biomedicine. --- Cancer Research. --- Pharmacology/Toxicology. --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemicals --- Drugs --- Pharmacy --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Pathology --- Physicians --- Physiological effect --- Toxicology. --- Pharmacology --- Poisoning --- Poisons --- Toxicology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Angiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies. This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials on therapeutic compounds are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in research and treatment in this exciting field.

Angiogenesis Inhibitors. --- Neoplasms -- drug therapy. --- Neovascularization inhibitors. --- Neovascularization, Pathologic -- drug therapy. --- Neovascularization inhibitors --- Neoplasms --- Angiogenesis Inhibitors --- Drug Therapy --- Neovascularization, Pathologic --- Therapeutics --- Diseases --- Angiogenesis Modulating Agents --- Metaplasia --- Antineoplastic Agents --- Growth Inhibitors --- Therapeutic Uses --- Growth Substances --- Pathologic Processes --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Pharmacologic Actions --- Physiological Effects of Drugs --- Pathological Conditions, Signs and Symptoms --- Chemical Actions and Uses --- Chemicals and Drugs --- Oncology --- Medicine --- Health & Biological Sciences --- Cancer --- Therapeutic use. --- Chemotherapy. --- Angiogenesis inhibitors --- Tumor angiogenesis inhibitors --- Medicine. --- Cancer research. --- Hematology. --- Oncology. --- Medicine & Public Health. --- Cancer Research. --- Tumors --- Haematology --- Internal medicine --- Blood --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Antineoplastic agents --- Treatment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The field of cancer biology and developmental therapeutics is continually evolving as new methodologies are developed and new targets are discovered. Although multiple therapeutics directly target the malignant cells these drugs rarely prevent recurrence of disease or the progression of metastasis. The complex biology of tumors presents challenges in designing treatments that will eliminate the malignant cells as well as the supporting network of vasculature and stroma that allows for the comparison of tumors to developing organs in embryos. In addition to blood vessels and malignant cells, tumors consist of fibroblasts, immune and inflammatory cells, and a myriad of proteins that comprise the extracellular matrix. Effective eradication of malignant disease requires therapeutic strategies that factor in targeting the tumor microenvironment. In the past decade, a new class of anticancer drugs has emerged that interferes with tumor angiogenesis; however the clinical benefit from treatment with the first generation antiangiogenic agents added to the standard of care is often modest. Thus, there remains a critical need to understand the tumor microenvironment and to develop anti-cancer therapies that address this aspect of malignant disease. The first edition of The Tumor Microenvironment is intended to give a current perspective on the role of the tumor microenvironment in malignant progression and detail strategies for novel therapies directed towards the cellular matrix. This book explores the many biological and physiological aspects of the tumor as a tissue and includes chapters on the variety of cells that influence tumor growth and spread as well as the cell-associated and soluble proteins that can promote invasion and metastasis. Several chapters describe endothelial cells and pericytes that form tumor vasculature. Insights into the role of progenitor and stem cells are included. The contribution of the supporting stroma is addressed in addition to cell-cell signaling and cell-matrix interactions. Additional chapters describe the influence of infiltrating cells of the immune system on tumor growth. The Tumor Microenvironment is the definitive text detailing cutting edge research by experts in the field and will be a valued resource in the study of this important area of cancer biology for many years to come.

Cancer cells -- Regulation. --- Cancer cells. --- Cancer invasiveness. --- Carcinogenesis. --- Tumors -- Metabolism. --- Carcinogenesis --- Tumors --- Cancer cells --- Chemistry, Pharmaceutical --- Angiogenesis Modulating Agents --- Cell Physiological Phenomena --- Medicine --- Diseases --- Growth Inhibitors --- Antineoplastic Agents --- Stem Cells --- Investigative Techniques --- Pharmacology --- Therapeutic Uses --- Growth Substances --- Phenomena and Processes --- Chemistry --- Cells --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Health Occupations --- Neoplasms --- Angiogenesis Inhibitors --- Tumor Microenvironment --- Drug Discovery --- Pathology --- Neoplastic Stem Cells --- Biological Science Disciplines --- Anatomy --- Physiological Effects of Drugs --- Natural Science Disciplines --- Disciplines and Occupations --- Pharmacologic Actions --- Chemical Actions and Uses --- Chemicals and Drugs --- Health & Biological Sciences --- Oncology --- Metabolism --- Growth --- Physiology, Pathological --- Tumors. --- Tumours --- Medicine. --- Cancer research. --- Pharmacology. --- Biomedicine. --- Cancer Research. --- Pharmacology/Toxicology. --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemicals --- Chemotherapy --- Drugs --- Pharmacy --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Physicians --- Physiological effect --- Pathology, Cellular --- Cysts (Pathology) --- Oncology. --- Toxicology. --- Poisoning --- Poisons --- Toxicology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Preface Tumor development and progression occur as a result of cumulative acquisition of genetic alterations affecting oncogenes and tumor suppressor genes. As a consequence of these alterations the arising tumor gains some fatal properties such as increased cell proliferation and decreased apoptosis, resulting in a net accumulation of tra- formed cells. Once a critical volume is achieved, lack of oxygen and nutrients limits further growth. To overcome this obstacle, the tumor cells initiate a program focused on the formation of new blood vessels within the host tissue. This process is termed tumor angiogenesis and contributes to the progression of most solid tumors and the formation of metastases. Since its discovery more than 30 years ago by Dr. Judah Folkman, tumor angiog- esis has been proposed as an ideal target for novel tumor therapies. Today the first anti-angiogenic compounds are available for the treatment of patients but their s- cess in the clinic is rather limited when given as monotherapies. This is in contrast to many preclinical results which revealed a much higher efficacy of these therapeutics in appropriate animal models. The reasons for this discrepancy are manifold, one being the existence of more than one angiogenic signaling system capable of driving tumor angiogenesis. Therefore it is no surprise that the inhibition of just one system is not sufficient to block the formation of new blood vessels in patients.

Neoplasms --- Angiogenesis Inhibitors --- Neovascularization, Pathologic --- Neovascularization inhibitors --- Tumors --- Neovascularization --- Néovascularisation --- Tumeurs --- drug therapy. --- therapeutic use. --- blood supply. --- Blood-vessels --- Inhibiteurs --- Vaisseaux sanguins --- Cancer -- Treatment. --- Tumors -- Blood-vessels. --- Tumors. --- Angiogenesis Modulating Agents --- Antineoplastic Agents --- Growth Inhibitors --- Diseases --- Metaplasia --- Growth Substances --- Pathologic Processes --- Therapeutic Uses --- Pathological Conditions, Signs and Symptoms --- Physiological Effects of Drugs --- Pharmacologic Actions --- Chemical Actions and Uses --- Chemicals and Drugs --- Oncology --- Medicine --- Health & Biological Sciences --- Antineoplastic agents. --- Neovascularization inhibitors. --- Neovascularization. --- Blood-vessels. --- Néovascularisation --- EPUB-LIV-FT LIVMEDEC LIVSANTE SPRINGER-B --- Angiogenesis --- Cancer --- Angiogenesis inhibitors --- Tumor angiogenesis inhibitors --- Anticancer agents --- Antineoplastic drugs --- Antineoplastics --- Antitumor agents --- Antitumor drugs --- Cytotoxic drugs --- Inhibitors, Neoplasm --- Neoplasm inhibitors --- Medicine. --- Cancer research. --- Molecular biology. --- Pharmacology. --- Oncology. --- Medicine & Public Health. --- Cancer Research. --- Molecular Medicine. --- Pharmacology/Toxicology. --- Antineoplastic agents --- Drugs --- Chemotherapy --- Growth --- Oncology  . --- Toxicology. --- Chemicals --- Pharmacology --- Poisoning --- Poisons --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Toxicology --- Health Workforce --- Drug effects --- Medical pharmacology --- Pharmacy --- Molecular biochemistry --- Molecular biophysics --- Biochemistry --- Biophysics --- Biomolecules --- Systems biology --- Cancer research --- Physiological effect